Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Jun. 30, 2021 | Aug. 11, 2021 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0000832489 | |
Entity Registrant Name | GeoVax Labs, Inc. | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2021 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 30, 2021 | |
Document Transition Report | false | |
Entity File Number | 001-39563 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 87-0455038 | |
Entity Address, Address Line One | 1900 Lake Park Drive, Suite 380 | |
Entity Address, City or Town | Smyrna | |
Entity Address, State or Province | GA | |
Entity Address, Postal Zip Code | 30080 | |
City Area Code | 678 | |
Local Phone Number | 384-7220 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Emerging Growth Company | false | |
Entity Small Business | true | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 6,327,702 | |
Warrant [Member] | ||
Document Information [Line Items] | ||
Title of 12(b) Security | Warrants to Purchase Common Stock | |
Trading Symbol | GOVXW | |
Security Exchange Name | NASDAQ | |
Common Stock [Member] | ||
Document Information [Line Items] | ||
Title of 12(b) Security | Common Stock $0.001 par value | |
Trading Symbol | GOVX | |
Security Exchange Name | NASDAQ |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
ASSETS | ||
Cash and cash equivalents | $ 19,538,513 | $ 9,883,796 |
Grant funds and other receivables | 0 | 182,663 |
Prepaid expenses and other current assets | 118,038 | 168,689 |
Total current assets | 19,656,551 | 10,235,148 |
Property and equipment, net | 149,799 | 147,741 |
Deposits | 11,010 | 11,010 |
Total assets | 19,817,360 | 10,393,899 |
Current liabilities: | ||
Accounts payable | 289,680 | 267,702 |
Accrued expenses | 69,342 | 359,281 |
Current portion of notes payable | 0 | 183,326 |
Total current liabilities | 359,022 | 810,309 |
Note payable, net of current portion | 0 | 14,738 |
Total liabilities | 359,022 | 825,047 |
Commitments (Note 8) | ||
Stockholders’ equity: | ||
Preferred Stock, $.01 par value: Authorized shares – 10,000,000: Series B convertible preferred stock, $1,000 stated value; Authorized shares – 10,000,000; 100 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively | 0 | 76,095 |
Common stock, $.001 par value; Authorized shares – 600,000,000; Issued and outstanding shares – 6,315,467 and 3,834,095 at March 31, 2021 and December 31, 2020, respectively | 6,328 | 3,834 |
Additional paid-in capital | 68,134,402 | 55,294,504 |
Accumulated deficit | (48,682,392) | (45,805,581) |
Total stockholders’ equity | 19,458,338 | 9,568,852 |
Total liabilities and stockholders’ equity | $ 19,817,360 | $ 10,393,899 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Jun. 30, 2021 | Dec. 31, 2020 |
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, stated value (in dollars per share) | 0.01 | 0.01 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, authorized (in shares) | 600,000,000 | 600,000,000 |
Common stock, issued (in shares) | 6,327,702 | 3,834,095 |
Common stock, outstanding (in shares) | 6,327,702 | 3,834,095 |
Series B Convertible Preferred Stock [Member] | ||
Preferred stock, par value (in dollars per share) | $ 1,000 | $ 1,000 |
Preferred stock, stated value (in dollars per share) | $ 1,000 | $ 1,000 |
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Preferred stock, shares issued (in shares) | 0 | 100 |
Preferred stock, shares outstanding (in shares) | 0 | 100 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Grant and collaboration revenue | $ 79,708 | $ 440,602 | $ 190,125 | $ 1,156,579 |
Operating expenses: | ||||
Research and development | 832,835 | 461,421 | 1,435,618 | 1,270,357 |
General and administrative | 733,499 | 427,292 | 1,805,209 | 929,637 |
Total operating expenses | 1,566,334 | 888,713 | 3,240,827 | 2,199,994 |
Loss from operations | (1,486,626) | (448,111) | (3,050,702) | (1,043,415) |
Other income (expense): | ||||
Interest income | 1,068 | 60 | 3,121 | 812 |
Interest expense | (531) | (7,153) | (1,286) | (8,295) |
Gain on debt extinguishment | 172,056 | 0 | 172,056 | 0 |
Total other income (expense) | 172,593 | (7,093) | 173,891 | (7,483) |
Net loss | $ (1,314,033) | $ (455,204) | $ (2,876,811) | $ (1,050,898) |
Basic and diluted: | ||||
Net loss per common share (in dollars per share) | $ (0.21) | $ (0.66) | $ (0.49) | $ (2.27) |
Weighted average shares outstanding (in shares) | 6,322,799 | 691,155 | 5,830,165 | 462,775 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) - USD ($) | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2019 | 2,486 | 14,992 | |||
Balance at Dec. 31, 2019 | $ 1,932,433 | $ 15 | $ 39,340,509 | $ (42,847,513) | $ (1,574,556) |
Issuance of common stock for services (in shares) | 521 | ||||
Issuance of common stock for services | $ 1 | 5,999 | 6,000 | ||
Net loss | (595,694) | (595,694) | |||
Balance (in shares) at Mar. 31, 2020 | 400 | 689,581 | |||
Balance at Mar. 31, 2020 | $ 376,095 | $ 690 | 41,202,172 | (43,443,207) | (1,864,250) |
Sale of convertible preferred stock for cash and cancellation of note payable (in shares) | 300 | ||||
Sale of convertible preferred stock for cash and cancellation of note payable | $ 300,000 | 300,000 | |||
Conversion of preferred stock to common stock (in shares) | (2,386) | 674,068 | |||
Conversion of preferred stock to common stock | $ (1,856,338) | $ 674 | 1,855,664 | ||
Balance (in shares) at Dec. 31, 2019 | 2,486 | 14,992 | |||
Balance at Dec. 31, 2019 | $ 1,932,433 | $ 15 | 39,340,509 | (42,847,513) | (1,574,556) |
Net loss | (1,050,898) | ||||
Balance (in shares) at Jun. 30, 2020 | 400 | 691,705 | |||
Balance at Jun. 30, 2020 | $ 376,095 | $ 692 | 41,672,003 | (43,898,411) | (1,849,621) |
Balance (in shares) at Mar. 31, 2020 | 400 | 689,581 | |||
Balance at Mar. 31, 2020 | $ 376,095 | $ 690 | 41,202,172 | (43,443,207) | (1,864,250) |
Issuance of common stock for services (in shares) | 0 | 2,124 | |||
Issuance of common stock for services | $ 0 | $ 2 | 11,998 | 0 | 12,000 |
Net loss | $ 0 | $ 0 | 0 | (455,204) | (455,204) |
Balance (in shares) at Jun. 30, 2020 | 400 | 691,705 | |||
Balance at Jun. 30, 2020 | $ 376,095 | $ 692 | 41,672,003 | (43,898,411) | (1,849,621) |
Warrants issued in bridge financing | $ 0 | $ 0 | 457,833 | 0 | 457,833 |
Balance (in shares) at Dec. 31, 2020 | 100 | 3,834,095 | |||
Balance at Dec. 31, 2020 | $ 76,095 | $ 3,834 | 55,294,504 | (45,805,581) | 9,568,852 |
Sale of common stock for cash (in shares) | 0 | 1,644,000 | |||
Sale of common stock for cash | $ 0 | $ 1,644 | 9,407,276 | 0 | 9,408,920 |
Common stock issued (in shares) | 0 | 835,900 | |||
Issuance of common stock upon warrant exercise | $ 0 | $ 836 | 3,173,320 | 0 | 3,174,156 |
Issuance of common stock for services (in shares) | 0 | 1,472 | |||
Issuance of common stock for services | $ 0 | $ 1 | 5,999 | 0 | 6,000 |
Stock option expense | 56,190 | 56,190 | |||
Net loss | (1,562,778) | (1,562,778) | |||
Balance (in shares) at Mar. 31, 2021 | 100 | 6,315,467 | |||
Balance at Mar. 31, 2021 | $ 76,095 | $ 6,315 | 67,937,289 | (47,368,359) | 20,651,340 |
Balance (in shares) at Dec. 31, 2020 | 100 | 3,834,095 | |||
Balance at Dec. 31, 2020 | $ 76,095 | $ 3,834 | 55,294,504 | (45,805,581) | $ 9,568,852 |
Issuance of common stock for services (in shares) | 13,707 | ||||
Net loss | $ (2,876,811) | ||||
Balance (in shares) at Jun. 30, 2021 | 0 | 6,327,702 | |||
Balance at Jun. 30, 2021 | $ 0 | $ 6,328 | 68,134,402 | (48,682,392) | 19,458,338 |
Balance (in shares) at Mar. 31, 2021 | 100 | 6,315,467 | |||
Balance at Mar. 31, 2021 | $ 76,095 | $ 6,315 | 67,937,289 | (47,368,359) | 20,651,340 |
Issuance of common stock for services (in shares) | 0 | 12,235 | |||
Issuance of common stock for services | $ 0 | $ 13 | 65,828 | 0 | 65,841 |
Stock option expense | 0 | 0 | 56,190 | 0 | 56,190 |
Net loss | $ 0 | $ 0 | 0 | (1,314,033) | (1,314,033) |
Repurchase of preferred stock (in shares) | (100) | 0 | |||
Repurchase of preferred stock | $ (76,095) | $ 0 | 75,095 | 0 | (1,000) |
Balance (in shares) at Jun. 30, 2021 | 0 | 6,327,702 | |||
Balance at Jun. 30, 2021 | $ 0 | $ 6,328 | $ 68,134,402 | $ (48,682,392) | $ 19,458,338 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Cash flows from operating activities: | ||
Net loss | $ (2,876,811) | $ (1,050,898) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 17,871 | 7,033 |
Stock-based compensation expense | 198,821 | 18,000 |
Gain on debt extinguishment | (172,056) | 0 |
Changes in assets and liabilities: | ||
Grant funds and other receivables | 182,663 | (118,560) |
Prepaid expenses and other current assets | 36,051 | 54,850 |
Accounts payable and accrued expenses | (266,105) | 164,082 |
Total adjustments | (2,755) | 125,405 |
Net cash used in operating activities | (2,879,566) | (925,493) |
Cash flows from investing activities | ||
Purchase of equipment | (19,929) | 0 |
Net cash used in investing activities | (19,929) | 0 |
Cash flows from financing activities: | ||
Net proceeds from sale of common stock | 9,408,920 | 0 |
Net proceeds from sale of preferred stock | 0 | 300,000 |
Net proceeds from warrant exercises | 3,174,156 | 0 |
Net proceeds from bridge financing | 0 | 888,500 |
Net proceeds from issuance of note payable | 0 | 170,200 |
Repurchase of preferred stock | (1,000) | 0 |
Principal repayment of note payable | (27,864) | (5,866) |
Net cash provided by financing activities | 12,554,212 | 1,352,834 |
Net increase in cash and cash equivalents | 9,654,717 | 427,341 |
Cash and cash equivalents at beginning of period | 9,883,796 | 283,341 |
Cash and cash equivalents at end of period | $ 19,538,513 | $ 710,682 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($) | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Paycheck Protection Program CARES Act [Member] | ||
Extinguishment of debt | $ 172,056 | |
Conversion of Series H Preferred Stock Into Common Stock [Member] | ||
Convertible preferred stock (in shares) | 1,686 | |
Conversion of stock, shares issued (in shares) | 469,697 | |
Conversion of Series I Preferred Stock Into Common Stock [Member] | ||
Convertible preferred stock (in shares) | 700 | |
Conversion of stock, shares issued (in shares) | 204,371 | |
Stock Purchase Warrants First Issuance [Member] | ||
Common stock issued (in shares) | 145,866 | |
Stock purchase warrants exercised (in shares) | 188,668 |
Note 1 - Description of Busines
Note 1 - Description of Business | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | 1. Description of Business GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using a novel vector vaccine platform (Modified Vaccinia Ankara (MVA) Virus-Like Particle, or “GV-MVA-VLP TM Our current development programs are focused on preventive vaccines against novel coronavirus (COVID- 19 GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area. |
Note 2 - Basis of Presentation
Note 2 - Basis of Presentation | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Basis of Accounting [Text Block] | 2. Basis of Presentation The accompanying condensed consolidated financial statements at June 30, 2021 three six June 30, 2021 2020 not 10 December 31, 2020. not We enacted reverse stock splits of our common stock on September 25, 2020 ( 1 January 21, 2020 ( 1 Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for at least the twelve We expect to incur future net losses and require substantial funds as we continue our research and development activities. Our transition to profitability will be dependent upon, among other things, the successful development and commercialization of our product candidates. We may may no |
Note 3 - Significant Accounting
Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 3. Significant Accounting Policies and Recent Accounting Pronouncements We disclosed in Note 2 10 December 31, 2020 six June 30, 2021, no 10 no |
Note 4 - Basic and Diluted Loss
Note 4 - Basic and Diluted Loss Per Common Share | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 4. Basic and Diluted Loss Per Common Share Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, totaled 583,336 and 503,785 shares for the three six June 30, 2021, three six June 30, 2020, |
Note 5 - Property and Equipment
Note 5 - Property and Equipment | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | 5. Property and Equipment Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of June 30, 2021 December 31, 2020: June 30, 2021 December 31, 2020 Laboratory equipment $ 543,912 $ 532,100 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 19,853 11,736 Total property and equipment 679,370 659,441 Accumulated depreciation and amortization (529,571 ) (511,700 ) Property and equipment, net $ 149,799 $ 147,741 |
Note 6 - Accrued Expenses
Note 6 - Accrued Expenses | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | 6. Accrued Expenses Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets are composed of the following as of June 30, 2021 December 31, 2020: June 30, 2021 December 31, 2020 Accrued salaries and directors’ fees $ - $ 279,696 Other accrued expenses 69,342 79,585 Total accrued expenses $ 69,342 $ 359,281 |
Note 7 - Notes Payable
Note 7 - Notes Payable | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 7. Notes Payable GRA Note February 28, 2018, five five three six June 30, 2021 2020. May 2021, CARES Act Paycheck Protection Program Loan April 17, 2020, one three six June 30, 2021, 2020. May 2021, |
Note 8 - Commitments
Note 8 - Commitments | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Commitments Disclosure [Text Block] | 8. Commitments Lease Agreement We lease approximately 8,400 square feet of office and laboratory space pursuant to an operating lease which expires on December 31, 2022. three six June 30, 2021 2020. 2021 2022, may ninety Other Commitments In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of June 30, 2021, 2021. |
Note 9 - Stockholders' Equity
Note 9 - Stockholders' Equity | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Preferred Stock [Text Block] | 9. Stockholders Equity Preferred Stock June 7, 2021, June 30, 2021, Public Offering February 11, 2021, three Stock Options “2020 may 2020 six June 30, 2021, no 2020 June 30, 2021, Stock Purchase Warrants January February 2021, June 30, 2021, Other Common Stock Transactions six June 30, 2021, 10 |
Note 10 - Stock-Based Compensat
Note 10 - Stock-Based Compensation Expense | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | 10. Stock-Based Compensation Expense Stock-based compensation expense related to employee and director stock options was $56,190 and $112,380 during the three six June 30, 2021, 2020. June 30, 2021, During the three six June 30, 2021, 2020. June 30, 2021, |
Note 11 - Income Taxes
Note 11 - Income Taxes | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 11. Income Taxes Because of our historically significant net operating losses, we have not 382 may |
Note 12 - Grants and Collaborat
Note 12 - Grants and Collaboration Revenue | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Government Grants and Contracts [Text Block] | 12. Grants and Collaboration Revenue We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the three six June 30, 2021, 2020. three six June 30, 2020, third June 30, 2021, 2021. |
Note 5 - Property and Equipme_2
Note 5 - Property and Equipment (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | June 30, 2021 December 31, 2020 Laboratory equipment $ 543,912 $ 532,100 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 19,853 11,736 Total property and equipment 679,370 659,441 Accumulated depreciation and amortization (529,571 ) (511,700 ) Property and equipment, net $ 149,799 $ 147,741 |
Note 6 - Accrued Expenses (Tabl
Note 6 - Accrued Expenses (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Schedule of Accrued Liabilities [Table Text Block] | June 30, 2021 December 31, 2020 Accrued salaries and directors’ fees $ - $ 279,696 Other accrued expenses 69,342 79,585 Total accrued expenses $ 69,342 $ 359,281 |
Note 2 - Basis of Presentation
Note 2 - Basis of Presentation (Details Textual) | Sep. 25, 2020 | Jan. 21, 2020 |
Reverse Stock Split [Member] | ||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 20 | 2,000 |
Note 4 - Basic and Diluted Lo_2
Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) - shares | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 583,336 | 67,009 | 503,785 | 55,191 |
Note 5 - Property and Equipme_3
Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Property and equipment, gross | $ 679,370 | $ 659,441 |
Accumulated depreciation and amortization | (529,571) | (511,700) |
Property and equipment, net | 149,799 | 147,741 |
Laboratory Equipment [Member] | ||
Property and equipment, gross | 543,912 | 532,100 |
Leasehold Improvements [Member] | ||
Property and equipment, gross | 115,605 | 115,605 |
Other Furniture Fixtures And Equipment [Member] | ||
Property and equipment, gross | $ 19,853 | $ 11,736 |
Note 6 - Accrued Expenses - Sch
Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) | Jun. 30, 2021 | Dec. 31, 2020 |
Accrued salaries and directors’ fees | $ 0 | $ 279,696 |
Other accrued expenses | 69,342 | 79,585 |
Total accrued expenses | $ 69,342 | $ 359,281 |
Note 7 - Notes Payable (Details
Note 7 - Notes Payable (Details Textual) - USD ($) | Apr. 17, 2020 | Feb. 28, 2018 | May 31, 2021 | Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 |
Proceeds from Notes Payable, Total | $ 0 | $ 170,200 | |||||
Repayments of Notes Payable | 27,864 | 5,866 | |||||
Paycheck Protection Program CARES Act [Member] | |||||||
Proceeds from Notes Payable, Total | $ 170,200 | ||||||
Interest Expense, Debt, Total | $ 233 | $ 345 | 653 | 345 | |||
Extinguishment of Debt, Amount | $ 170,200 | ||||||
Gain (Loss) from Interest Forgiven | 1,856 | ||||||
Senior Notes [Member] | |||||||
Debt Instrument, Term (Year) | 5 years | ||||||
Proceeds from Notes Payable, Total | $ 50,000 | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | ||||||
Interest Expense, Debt, Total | $ 297 | $ 448 | $ 633 | $ 933 | |||
Repayments of Notes Payable | $ 22,737 |
Note 8 - Commitments (Details T
Note 8 - Commitments (Details Textual) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021USD ($)ft² | Jun. 30, 2020USD ($) | Jun. 30, 2021USD ($)ft² | Jun. 30, 2020USD ($) | |
Unrecorded Unconditional Purchase Obligation, Total | $ 1,047,000 | $ 1,047,000 | ||
Unrecorded Unconditional Purchase Obligation Reimbursable, Amount | $ 211,326 | $ 211,326 | ||
Office and Laboratory Lease Agreement [Member] | ||||
Area of Real Estate Property (Square Foot) | ft² | 8,400 | 8,400 | ||
Operating Lease, Expense | $ 42,803 | $ 41,539 | $ 85,607 | $ 83,078 |
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | 85,607 | 85,607 | ||
Lessee, Operating Lease, Liability, to be Paid, Year One | $ 176,356 | $ 176,356 |
Note 9 - Stockholders' Equity (
Note 9 - Stockholders' Equity (Details Textual) - USD ($) | Jun. 07, 2021 | Feb. 11, 2021 | Feb. 28, 2021 | Jun. 30, 2021 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 |
Stock Repurchased During Period, Value | $ 1,000 | ||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,644,000 | ||||||
Shares Issued, Price Per Share (in dollars per share) | $ 6.25 | ||||||
Proceeds from Issuance of Common Stock | $ 9,400,000 | $ 9,408,920 | $ 0 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 602,000 | 602,000 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ 2.79 | $ 2.79 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year) | 9 years 4 months 24 days | ||||||
Proceeds from Warrant Exercises | $ 3,174,156 | $ 3,174,156 | $ 0 | ||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 13,707 | ||||||
Stock Incentive Plan 2020 [Member] | |||||||
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 1,500,000 | 1,500,000 | |||||
Representative Warrants [Member] | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 72,000 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 6.875 | ||||||
Class of Warrant or Right, Period for Warrants or Rights Exercisable (Day) | 180 days | ||||||
Warrants and Rights Outstanding, Term (Year) | 3 years | ||||||
Stock Purchase Warrants First Issuance [Member] | |||||||
Class of Warrant or Right, Exercised During Period (in shares) | 188,688 | 188,668 | |||||
Stock Issued During Period, Shares, Warrants Exercised (in shares) | 145,866 | 145,866 | |||||
Stock Purchase Warrants Second Issuance [Member] | |||||||
Class of Warrant or Right, Exercised During Period (in shares) | 690,034 | ||||||
Stock Issued During Period, Shares, Warrants Exercised (in shares) | 690,034 | ||||||
Stock Purchase Warrants [Member] | |||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 5.07 | $ 5.07 | |||||
Warrants and Rights Outstanding, Term (Year) | 4 years 1 month 6 days | 4 years 1 month 6 days | |||||
Class of Warrant or Right, Outstanding (in shares) | 2,793,635 | 2,793,635 | |||||
Over-Allotment Option [Member] | |||||||
Stock Issued During Period, Shares, New Issues (in shares) | 204,000 | ||||||
Series B Convertible Preferred Stock [Member] | |||||||
Stock Repurchased During Period, Shares (in shares) | 100 | ||||||
Stock Repurchased During Period, Value | $ 1,000 | ||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 0 | 0 | 100 |
Note 10 - Stock-Based Compens_2
Note 10 - Stock-Based Compensation Expense (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $ 543,130 | $ 543,130 | ||
Stock Issued During Period, Value Expensed During the Period, Issued for Services | 30,573 | $ 12,000 | 51,173 | $ 18,000 |
Prepaid Expense, Value of Stock Issued for Services During Period | 69,333 | 69,333 | ||
Share-based Payment Arrangement, Option [Member] | ||||
Share-based Payment Arrangement, Expense | $ 56,190 | $ 0 | $ 112,380 | $ 0 |
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 2 years 4 months 24 days |
Note 11 - Income Taxes (Details
Note 11 - Income Taxes (Details Textual) $ in Thousands | 6 Months Ended |
Jun. 30, 2021USD ($) | |
Income Taxes Paid | $ 0 |
Note 12 - Grants and Collabor_2
Note 12 - Grants and Collaboration Revenue (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Revenue from Contract with Customer, Including Assessed Tax | $ 79,708 | $ 440,602 | $ 190,125 | $ 1,156,579 |
Unused Grant Funds | 275,302 | 275,302 | ||
NIH Grants [Member] | ||||
Revenue from Contract with Customer, Including Assessed Tax | $ 79,708 | 301,493 | $ 190,125 | 955,514 |
Leidos, Inc. Research Collaborative Agreement [Member] | ||||
Revenue from Contract with Customer, Including Assessed Tax | $ 139,109 | $ 201,065 |